13 Part VI: Summary of the risk management plan for ambrisentan 5mg and 10mg film-coated tablets

This is a summary of the risk management plan (RMP) for ambrisentan 5mg and 10mg film-coated tablets. The RMP details important risks of ambrisentan 5mg and 10mg film-coated tablets, how these risks can be minimized, and how more information will be obtained about ambrisentan 5mg and 10mg film-coated tablets' risks and uncertainties (missing information).

Ambrisentan 5mg and 10mg film-coated tablets' summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how ambrisentan 5mg and 10mg film-coated tablets should be used.

13.1 Part VI: I. The medicine and what it is used for

Ambrisentan 5mg and 10mg film-coated tablets are authorised for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see SmPC for the full indication). It contains ambrisentan as the active substance and it is given by 5mg or 10mg oral tablets.

13.2 Part VI: II. Risks associated with the medicine and activities to minimize or further characterize the risks

Important risks of ambrisentan 5mg and 10mg film-coated tablets, together with measures to minimize such risks and the proposed studies for learning more about ambrisentan 5mg and 10mg film-coated tablets' risks, are outlined below.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimize its risks.

Together, these measures constitute *routine risk minimization* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of ambrisentan 5mg and 10mg film-coated tablets is not yet available, it is listed under 'missing information' below.

13.2.1 Part VI – II.A: List of important risks and missing information

Important risks of ambrisentan 5mg and 10mg film-coated tablets are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of

ambrisentan 5mg and 10mg film-coated tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table 13-1 List of important risks and missing information

List of important risks and missing information	
Important identified risks	Teratogenicity
	Decreased haemoglobin, haematocrit, anaemia including anaemia requiring transfusion
	Hepatotoxicity
Important potential risk	Testicular tubular atrophy/ Male infertility
Missing information	None

13.2.2 Part VI – II.B: Summary of important risks

Table 13-2 Important identified risk 1: Teratogenicity (birth defects)

Risk minimization measures	**Routine risk minimization measures:** Information is included in Sections 4.3, 4.4 and 4.6 of the SmPC. Section 2 of the PL. This is a prescription only medication. **Additional risk minimization measures:** Patient reminder card

Table 13-3 Important identified risk 2: Hepatotoxicity (Liver damage)

Risk minimization measures	**Routine risk minimization measures:** Information is included in Sections 4.2, 4.3, 4.4 and 4.8 of the SmPC. Sections 2 adn 4 of the PL. This is a prescription only medication. **Additional risk minimization measures:** Patient reminder card

13.2.3 Part VI – II.C: Post-authorization development plan

13.2.3.1 II.C.1 Studies which are conditions of the marketing authorization

There are no studies which are conditions of the marketing authorization or specific obligation of ambrisentan 5mg and 10mg film-coated tablets.

13.2.3.2 II.C.2. Other studies in post-authorization development plan

There are no studies required for ambrisentan 5mg and 10mg film-coated tablets.